Merus Stock Surges Over 35% On Strong Phase 2 Cancer Trial Results: What's Going On? - Merus (NASDAQ:MRUS)

Merus Stock Surges Over 35% On Strong Phase 2 Cancer Trial Results: What's Going On? - Merus (NASDAQ:MRUS)

Merus N.V. (NASDAQ:MRUS) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab for head and neck cancer. What To Know: The data, which will be formally presented at the 2025 ASCO Annual Meeting, showed a 63% overall response rate and a 79% 12-month overall survival rate among 43 evaluable patients with PD-L1+ ...Full story ava…

Biotech Soars On 'Unprecedented' Results, Slamming Its Rival

Merus stock rocketed — and hammered Bicara — after unveiling promising new results for its experimental head-and-neck cancer treatment.

Merus drug, with immunotherapy, shows preliminary survival boost for patients with head and neck cancer

In a mid-stage trial, 79% of patients with newly diagnosed metastatic head and neck cancer lived for at least one year

Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025

· BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile and potentially promising efficacy signals as second-line treatment in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).…

Merus’ Phase 2 overall survival data reach ‘home run’ scenario

Merus completed its rollout of Phase 2 head and neck cancer data on Thursday, touting overall survival results that at least one analyst said amount to a best-case outcome. In the trial, patients got Merus' ...

Clinical Trial: Merus Cancer Drug Achieves 63% Response Rate, 79% Survival in Head & Neck Cancer Patients

New phase 2 data reveals impressive 63% response rate in head & neck cancer treatment. Learn how this combination therapy achieved 79% survival rate. See full results.